AstraZeneca plc’s (AZN) Hold Rating Reiterated at Shore Capital

Shore Capital reaffirmed their hold rating on shares of AstraZeneca plc (LON:AZN) in a report published on Tuesday.

Other research analysts also recently issued reports about the stock. J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a research report on Thursday, July 13th. UBS AG set a GBX 5,150 ($68.43) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research report on Tuesday, June 27th. Credit Suisse Group lowered their price objective on shares of AstraZeneca plc from GBX 5,000 ($66.44) to GBX 4,700 ($62.45) and set a neutral rating for the company in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.82) price objective on shares of AstraZeneca plc and gave the company a sell rating in a research report on Wednesday, August 2nd. Finally, HSBC Holdings plc downgraded shares of AstraZeneca plc to a reduce rating and set a GBX 4,500 ($59.79) price objective for the company. in a research report on Tuesday, July 4th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca plc presently has an average rating of Hold and an average target price of GBX 5,172.64 ($68.73).

AstraZeneca plc (AZN) traded down 0.25% during midday trading on Tuesday, reaching GBX 5162.00. The company had a trading volume of 1,809,138 shares. The company’s market capitalization is GBX 65.35 billion. The stock’s 50 day moving average is GBX 4,904.35 and its 200 day moving average is GBX 4,912.64. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://ledgergazette.com/2017/10/20/astrazeneca-plcs-azn-hold-rating-reiterated-at-

Other research analysts also recently issued reports about the stock. J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a research report on Thursday, July 13th. UBS AG set a GBX 5,150 ($68.43) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research report on Tuesday, June 27th. Credit Suisse Group lowered their price objective on shares of AstraZeneca plc from GBX 5,000 ($66.44) to GBX 4,700 ($62.45) and set a neutral rating for the company in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.82) price objective on shares of AstraZeneca plc and gave the company a sell rating in a research report on Wednesday, August 2nd. Finally, HSBC Holdings plc downgraded shares of AstraZeneca plc to a reduce rating and set a GBX 4,500 ($59.79) price objective for the company. in a research report on Tuesday, July 4th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca plc presently has an average rating of Hold and an average target price of GBX 5,172.64 ($68.73).

AstraZeneca plc (AZN) traded down 0.25% during midday trading on Tuesday, reaching GBX 5162.00. The company had a trading volume of 1,809,138 shares. The company’s market capitalization is GBX 65.35 billion. The stock’s 50 day moving average is GBX 4,904.35 and its 200 day moving average is GBX 4,912.64. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://ledgergazette.com/2017/10/20/astrazeneca-plcs-azn-hold-rating-reiterated-at-shore-capital.html.

In related news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were purchased at an average price of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply